Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Ironwood Pharmaceuticals (IRWD) EBIAT (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBIAT for 16 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 200.89% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2025, up 2629.2% year-over-year, with the annual reading at $24.0 million for FY2025, 2629.2% up from the prior year.
  • EBIAT hit -$2.3 million in Q4 2025 for Ironwood Pharmaceuticals, down from $40.1 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $391.3 million in Q2 2021 to a low of -$1.1 billion in Q2 2023.
  • Historically, EBIAT has averaged -$13.8 million across 5 years, with a median of $30.3 million in 2022.
  • Biggest five-year swings in EBIAT: plummeted 2964.58% in 2023 and later skyrocketed 2844.07% in 2025.
  • Year by year, EBIAT stood at $41.4 million in 2021, then grew by 18.11% to $48.9 million in 2022, then crashed by 103.57% to -$1.7 million in 2023, then surged by 229.28% to $2.3 million in 2024, then plummeted by 200.89% to -$2.3 million in 2025.
  • Business Quant data shows EBIAT for IRWD at -$2.3 million in Q4 2025, $40.1 million in Q3 2025, and $23.6 million in Q2 2025.